Urs J. Hancox

Biochemistry, Genetics and Molecular Biology · Life Sciences

10h-index673citations68works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

PI3K/AKT/mTOR signaling in cancer(36), Advanced Breast Cancer Therapies(34), Cancer Genomics and Diagnostics(21), Lung Cancer Treatments and Mutations(10), Cancer Treatment and Pharmacology(10)

Publications68 total

Supplementary Figure S1 from Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for <i>PIK3CA</i>-Dependent Breast Cancers
2023Open Access
Data from Inhibition of PI3Kβ Signaling with AZD8186 Inhibits Growth of PTEN-Deficient Breast and Prostate Tumors Alone and in Combination with Docetaxel
2023Open Access
Supplementary Figure S1 from Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for <i>PIK3CA</i>-Dependent Breast Cancers
2023Open Access
Supplementary Figure S6 from Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for <i>PIK3CA</i>-Dependent Breast Cancers
2023Open Access
Supplementary Table S3 from Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for <i>PIK3CA</i>-Dependent Breast Cancers
2023Open Access
Supplementary Table S4 from Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for <i>PIK3CA</i>-Dependent Breast Cancers
2023Open Access
Supplementary Figure S5 from Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for <i>PIK3CA</i>-Dependent Breast Cancers
2023Open Access
Supplementary Tables 1-3 and Figure 1-7 from Inhibition of PI3Kβ Signaling with AZD8186 Inhibits Growth of PTEN-Deficient Breast and Prostate Tumors Alone and in Combination with Docetaxel
2023Open Access
Supplementary Figure S3 from Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for <i>PIK3CA</i>-Dependent Breast Cancers
2023Open Access
Supplementary Table S2 from Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for <i>PIK3CA</i>-Dependent Breast Cancers
2023Open Access
Supplementary File S1 from Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for <i>PIK3CA</i>-Dependent Breast Cancers
2023Open Access
Data from Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for <i>PIK3CA</i>-Dependent Breast Cancers
2023Open Access
Supplementary Tables 1-3 and Figure 1-7 from Inhibition of PI3Kβ Signaling with AZD8186 Inhibits Growth of PTEN-Deficient Breast and Prostate Tumors Alone and in Combination with Docetaxel
2023Open Access
Supplementary Figure S4 from Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for <i>PIK3CA</i>-Dependent Breast Cancers
2023Open Access
Supplementary Materials text from Inhibition of PI3Kβ Signaling with AZD8186 Inhibits Growth of PTEN-Deficient Breast and Prostate Tumors Alone and in Combination with Docetaxel
2023Open Access
Data from Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for <i>PIK3CA</i>-Dependent Breast Cancers
2023Open Access
Supplementary Table S2 from Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for <i>PIK3CA</i>-Dependent Breast Cancers
2023Open Access
Supplementary Table S3 from Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for <i>PIK3CA</i>-Dependent Breast Cancers
2023Open Access
Supplementary Table S5 from Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for <i>PIK3CA</i>-Dependent Breast Cancers
2023Open Access
Supplementary Figure S7 from Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for <i>PIK3CA</i>-Dependent Breast Cancers
2023Open Access
page 1 of 4Next →

Frequent Co-authors

Rebecca Ellston(40), Marie Cumberbatch(37), Lara Ward(35), Urszula M. Polanska(35), Sabina Cosulich(33), Francisco Cruzalegui(32), Robert McEwen(31), Oona Delpuech(31), Alvaro Avivar‐Valderas(30), Cath Trigwell(27), Lyndsey Hanson(27), Stephen Green(24), Kevin Hudson(24), Pablo Morentin Gutierrez(21), Phillippa Dudley(21), Alys Jones(21), Myria Nikolaou(20), Simon T. Barry(18), Carol Lenaghan(15), Bernard Barlaam(13)